Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTOPRNewsWire • 04/18/24
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended PregnancyPRNewsWire • 03/07/24
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023PRNewsWire • 02/01/24
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFMBusiness Wire • 12/18/23
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with AditxtPRNewsWire • 12/12/23
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents ExpirePRNewsWire • 09/27/23
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock ExchangePRNewsWire • 08/22/23
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 04/28/23
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization RequiredPRNewsWire • 04/12/23
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for PhexxiPRNewsWire • 02/27/23
Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder ValuePRNewsWire • 02/23/23
Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)PRNewsWire • 01/12/23